Enzalutamide, a second generation androgen receptor antagonist used as standard of care therapy in various PCa clinical settings, has also been shown to increase NK cells and may be a viable addition to the tuvusertib + N-803 combination [55, 56]. This evidence concerns the gene AR and posterior cortical atrophy.